Intersect ENT — Investor Presentation (January 2016)
28 slides from Intersect ENT's investor presentation, Jan 11, 2016
Slide 1: Company Presentation January 2016
JANUARY 2016 Company Presentation Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this presentation constitute “forward-looking statements” within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), and Securities Exchange Act of 1934, as amended (“Exchange Act”), including, without limitation, statements
Slide 3: Our Focus
Our Focus Chronic Sinusitis 30M+ Patients in US Our Solutions Local, Sustained Drug Delivery via Dissolvable Implants Improving Quality of Life for Ear, Nose and Throat Patients
Slide 4: Chronic Sinusitis Today
Chronic Sinusitis Today Oral Steroids Sprays, Nebulizers, Irrigations DEBILITATING AND COSTLY CONDITION Sinus Packing There Is a Better Way
Slide 5: Challenges Across the Continuum of Care
Challenges Across the Continuum of Care to Create and Maintain Sinus Patency, Treat Inflammation and Deliver Steroid Safely and Effectively CS Treatment Pathway Oral Steroids Reduce Inflammation but Can Cause Side Effects MEDICATION TO TREAT Surgery Opens Pathways but Can Result in Post-Operative Sc
Slide 6: Technology Portfolio Across Continuum of Care
Mechanical Spacing and Local Drug Delivery via Bioabsorbable Implant Technology Portfolio Across Continuum of Care NOVA and RESOLVE are investigational and not currently available for sale in the United States. The implants are limited by federal (or United States) law to investigational use only. P
Slide 7: Large US Market Opportunity
Large US Market Opportunity PATIENTS 800K 540K 635K SIZE $1.1B $830M $1.3B $3B+ in US NOVA and RESOLVE are investigational and not currently available for sale in the United States. The implants are limited by federal (or United States) law to investigational use only. PRIMARY CS Office RECURRENT CS
Slide 8: Intersect ENT Opportunity
Intersect ENT Opportunity LARGE MARKET $3B+ TAM in US UNIQUE PRODUCTS 1st and Only Drug Releasing Implants in ENT PRODUCT PIPELINE In-Office Products to Serve Continuum of Care COMMERCIAL GROWTH 2015 Preliminary Revenue Growth 60% over 2014 *Preliminary estimate based on currently available informat
Slide 9: Two Commercial Products
Two Commercial Products 1st Drug Releasing Implants for Chronic Sinusitis Patients Only PMA Approval for CS Patients ~ 100,000 Patients to Date IMPROVING SURGICAL OUTCOMES Reduced Inflammation, Scarring and Need for Additional Surgery and Oral Steroids
Slide 10: PROPEL / PROPEL MINI How It Works
PROPEL / PROPEL MINI How It Works Advanced into Surgically Enlarged Sinus Cavity OPENS Self-Expanding Implant Conforms to and Holds Open Sinus DELIVERS Sustained, Targeted Delivery of Steroid Over 30 Days MAINTAINS Opening by Reducing Post-Operative Inflammation and Scarring ETHMOID SINUS
Slide 11: PROPEL Clinically Proven Surgical Outcomes
PROPEL Clinically Proven Surgical Outcomes 3 Prospective Trials, 200+ Patients Only Device Used in Sinus Surgery Backed by Level 1a Evidence Reduction in Post-Operative Medical and Surgical Interventions Meta-Analysis of Two Prospective, Multicenter, Randomized, Controlled, Double-Blind Studies POST
Slide 12: 2015 Success and Our Market
2015 SUCCESS OUR MARKET $61.4 - $61.6M* Revenue 60% Growth YoY 74 Territories (42% YoY) 7,500 Target ENTs ~540,000 Surgeries PROPEL Commercial Opportunity 4 Years 30% Penetration HOUSTON 1 Year 6% Penetration KANSAS 4 Years 50% Penetration NEW YORK CITY 1½ Years 8% Penetration ALABAMA 25% of ENTs <1
Slide 13: PROPEL Physician Adoption
PROPEL Physician Adoption Selective Use More severe patients, polyps Cost sensitive environment Broad Use Value clinical benefits across majority of patients Early tech adopters Key Drivers to Expand PROPEL Usage Peer to Peer Education Market Development Approval of Frontal Indication New Reimbursem
Slide 14: PROPEL FESS: Well-Reimbursed Procedure
PROPEL FESS: Well-Reimbursed Procedure *Rates depicted assume a surgical case including bilateral endoscopic procedures on ethmoid, maxillary and frontal sinuses. Commercial payor rates are calculated as 135% of National Medicare average payment rates for the same procedure mix. Commercial payor rat
Slide 15: PROPEL Product Cost Offset by Clinical and Economic Value
PROPEL Product Cost Offset by Clinical and Economic Value 1Rudmik L and Smith TL. Economic Evaluation of a Steroid-Eluting Sinus Implant following Endoscopic Sinus Surgery for Chronic Rhinosinusitis. Otolaryngol Head Neck Surg. 2014 May 5;151(2):359-366. 2Rudmik L, Mallow P, Swetha, P and Rizzo, J.
Slide 16: PROPEL MINI Expanding Indications
PROPEL MINI Expanding Indications FRONTAL SINUS Seeking Expanded Indication for Placement in Frontal Sinus 25-30% of Sinus Surgeries UPDATE 38% Reduction in Post-Operative Medical and Surgical Interventions Demonstrated in PROGRESS 80 Patient Prospective, Randomized, Blinded, Multi-Center Trial Met
Slide 17: In-Office Solutions
In-Office Solutions FESS Surgery PRIMARY CS Office NOVA RECURRENT CS Office RESOLVE PROPEL MEDICATION TO TREAT MANAGEMENT TO MAINTAIN SURGERY TO OPEN *NOVA and RESOLVE are in clinical development and have not been approved for commercial sale
Slide 18: RESOLVE How It Works
RESOLVE How It Works Investigational Drug Only. Not approved for sale in U.S. Patients Who Have Had Prior Surgery Dilates Obstructed Cavity Delivers~4x Steroid (vs. PROPEL) Over 90 Days Regulatory Path: NDA Less Invasive, More Cost Effective vs. Revision Surgery IN-OFFICE TREATMENT FOR RECURRENT CRS
Slide 19: RESOLVE Promising Results
RESOLVE Promising Results Change from Baseline in Endoscopic and Symptom Scores vs. Sham Procedure. Format modified from Han JK, Forwith KD, Smith TL, et al. RESOLVE: a randomized, controlled, blinded study of bioabsorbable steroid releasing sinus implants for in-office treatment of recurrent sinona
Slide 20: NOVA How It Works
NOVA How It Works Investigational Device Only. Not approved for sale in U.S. Primary (Including Post Dilation) or Revision Patients Hourglass Shape to Maximize Tissue Apposition and Support Regulatory Pathway: PMA-s PROGRESS Nova Trial Commenced July 2015 in Frontal Sinus IN-OFFICE or SURGICAL SOLUT
Slide 21: Industry Landscape
Industry Landscape We Are a Unique Solution – Complementary to Other Technologies STEROIDS SURGICAL TOOLS / SUPPLIES
Slide 22: Multiple Barriers to Entry
Multiple Barriers to Entry REGULATORY Only Drug Releasing Implants in ENT Two PMA Approvals RESOLVE: NDA Pathway R&D / MANUFACTURING 50,000 ft2 Facility in Menlo Park, CA Specialized Capabilities in Bioabsorbable DES Robust Quality System INTELLECTUAL PROPERTY 59 Issued Patents 37 Pending Patents Co
Slide 23: Outlook: Clinical Milestones
Outlook: Clinical Milestones NOVA RESOLVE PROPEL 2015 2016 2017 2018 PROPEL mini Frontal Approval PMA-s Approval (Frontal) Frontal PMA-s Submitted NDA Approval RESOLVE II Enrollment PROGRESS Nova Enrollment
Slide 24: Emerging Opportunity Outside the US
Emerging Opportunity Outside the US ~540K FESS / Year ~450K FESS / Year ~250K FESS / Year ATTRACTIVE MARKET OPPORTUNITIES Targeting 4-6 Large Markets in Europe and Asia Pacific PROPEL Has CE Mark Approval DEVELOPING MARKET COMMERCIALIZATION PLANS Regulatory Pathways (Especially China, Japan) KOL Sup
Slide 25: Experienced Leadership
Experienced Leadership MANAGEMENT TEAM LISA EARNHARDT President & CEO RICH KAUFMAN COO, SVP R&D & Operations JERI HILLEMAN CFO ROB BINNEY VP Sales SUSAN STIMSON VP Marketing JAMES STAMBAUGH VP Clinical Affairs AMY WOLBECK VP Regulatory Affairs & Quality CHAS McKHANN Chief Commercial Officer EXPERIEN
Slide 26: Intersect ENT Opportunity
Intersect ENT Opportunity LARGE MARKET $3B+ TAM in US UNIQUE PRODUCTS 1st and Only Drug Releasing Implants in ENT PRODUCT PIPELINE In-Office Products to Serve Continuum of Care COMMERCIAL GROWTH *Preliminary estimate based on currently available information. Has not been audited or reviewed by our i
Slide 27: $3B+ US Market
$3B+ US Market 1st and ONLY Drug Releasing Implants in ENT PORTFOLIO to Treat Continuum of Care TRACK RECORD Strong Revenue Growth & GMs
Slide 28: Intersect ENT
intersect’ ENT NASDAQ: XENT